Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Dexcom (DXCM) Long-Term Debt Issuances (2017 - 2018)

Dexcom (DXCM) reported Long-Term Debt Issuances of $836.6 million for Q4 2018, up 166.43% year-over-year from $314.0 million in Q4 2017, and up 166.43% on a QoQ basis from $314.0 million in Q4 2017.

Dexcom (DXCM) has 2 years of Long-Term Debt Issuances data on file, last reported at $836.6 million in Q4 2018.

  • Quarterly Long-Term Debt Issuances rose 166.43% year-over-year to $836.6 million in Q4 2018, while the trailing twelve-month figure through Sep 2020 was $836.6 million (changed 0.0% YoY) and the FY2023 annual result came in at $1.2 billion, changed N/A from the prior year.
  • Long-Term Debt Issuances climbed to $836.6 million in Q4 2018 per DXCM's latest filing, from $314.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $836.6 million in Q4 2018 and bottomed at $75.0 million in Q1 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 19.86 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn 11.71 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn 1.15 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Zimmer Biomet Holdings 16.17 Bn 15.75 Bn 1.51 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2018 836.60 Mn
Dec 31, 2018 836.60 Mn
Dec 31, 2017 314.00 Mn
Dec 31, 2017 314.00 Mn
Sep 30, 2017 389.00 Mn
Sep 30, 2017 389.00 Mn
Jun 30, 2017 389.00 Mn
Jun 30, 2017 389.00 Mn
Mar 31, 2017 75.00 Mn
Mar 31, 2017 75.00 Mn